Why Biomarker Discovery Matters
Precision medicine depends on robust biomarkers. The companion diagnostics market exceeds $6 billion, growing at 12% annually. ML algorithms mine high-dimensional omics datasets to uncover signatures that traditional statistical approaches miss.
ML Approaches
Random forests provide feature importance rankings. Deep learning autoencoders compress data into latent representations capturing non-linear relationships. Multi-omics integration learns joint representations across genomic, proteomic, and metabolomic data.
Case Study: NSCLC Immunotherapy Response
A Swiss diagnostics firm identified a 12-gene signature predictive of pembrolizumab response. Validated across 1,200 patients with AUC of 0.89 (vs. 0.71 for PD-L1 alone).
Regulatory Pathway
- IVDR compliance for EU market access
- Swissmedic alignment through mutual recognition
- FDA expectations for AI/ML-based SaMD